Streetbeat News

MLTX

MoonLake Immunotherapeutics

https://www.moonlaketx.com

Industry

Biotechnology

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Open

51.98

Mkt cap

3.1B

Volume

401K

High

51.98

P/E Ratio

-38.45

52-wk high

64.98

Low

48.30

Div yield

N/A

52-wk low

37.55

Needham analyst Serge Belanger has reiterated a Buy rating on MoonLake (NASDAQ:MLTX) and maintained a $66 price target.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:46 am

MoonLake Immunotherapeutics (NASDAQ:MLTX) announced it will present 24-week data from its Phase 2 MIRA trial of sonelokimab for hidradenitis suppurativa at the AAD Annual Meeting 2024. The data, showcasing the therapeutic effect of sonelokimab, marks a significant step in its development for treating this chronic skin condition. Previously, MoonLake reported positive 12-week data and further validated these findings with 24-week results, positioning sonelokimab as a promising therapy for HS.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 1:04 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on MoonLake (NASDAQ:MLTX) and maintained a $75 price target.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:45 pm

The Cooper Companies reported better-than-expected Q1 financial results and raised guidance, leading to a 7.4% stock increase. Other companies like Dell, Sweetgreen, Everbridge, NetApp, and Tidewater also saw significant gains following positive financial results or corporate actions. Stocks like Dell and NetApp reported better-than-expected financial results, with Dell also increasing its annual cash dividend by 20%. Everbridge amended a merger agreement, and Tidewater reported strong Q4 results.

Portfolio Pulse from Avi Kapoor

March 01, 2024 | 4:18 pm

Wedbush analyst Andreas Argyrides reiterates an Outperform rating on MoonLake (NASDAQ:MLTX) and maintains a $92 price target.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:40 pm

Needham analyst Serge Belanger has reiterated a Buy rating on MoonLake (NASDAQ:MLTX) and maintained a $66 price target.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 10:28 am

Wolfe Research analyst Andy Chen initiates coverage on MoonLake (NASDAQ:MLTX) with an Outperform rating, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:00 pm

In Wednesday's after-market session, several healthcare stocks experienced significant movements. Atara Biotherapeutics (ATRA) saw a 24.3% increase, while MoonLake (MLTX) rose by 12.98%. TC BioPharm (TCBP), Perspective Therapeutics (CATX), Lucy Scientific Discovery (LSDI), and Calliditas Therapeutics (CALT) also posted gains. Conversely, Jin Medical International (ZJYL) led the losers with a 10.7% decline, followed by Avalo Therapeutics (AVTX), Eiger BioPharmaceuticals (EIGR), Monogram Orthopaedics (MGRM), LogicMark (LGMK), and Aclarion (ACON) with notable decreases.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 9:31 pm

Stifel analyst Alex Thompson has maintained a Buy rating on MoonLake (NASDAQ:MLTX) and increased the price target from $66 to $69.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:37 pm

MoonLake Immunotherapeutics' stock is trading higher following Citigroup's initiation of coverage with a Buy rating and a $72 price target.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 3:50 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.